Examination of the efficacy of the MRI-TRUS fusion biopsy (Biojet) system against prostate cancer

Examination of the efficacy of the MRI-TRUS fusion biopsy (Biojet) system against prostate cancer - Biojet system for the prostate biopsy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026709

Enrollment

Registered

2017-03-27

Start date

2017-03-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) PSA level (2.8-50ng/ml) 2) Suspicious of localized prostate cancer by digital rectal examination 3) Suspicious of localized prostate cancer by MRI 4) patients who was obtained informed consent

Exclusion criteria

Exclusion criteria: 1) Suspicious of invasive prostate cancer by digital rectal examination 2) Suspicious of invasive prostate cancer by MRI 3) Patients with coagulation disorder 4) Patients who can not be performed TRUS because of anal stenosis

Design outcomes

Primary

Measure	Time frame
The detection rate of clinically significant prostate cancer	—

Countries

Japan

Contacts

Public ContactShuzo Hamamoto

Nagoya City University Graduate School of Medical Sciences Nephro-urology

hamamo10@med.nagoya-cu.ac.jp052-853-8266

Outcome results